オクラホマにおける転移性癌の臨床試験
オクラホマ内の拠点で、転移性癌に関する16件の研究が参加者を募集しています。
オクラホマ内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Oklahoma, Oklahoma City
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT05803382Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- University of Oklahoma, Oklahoma City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213804Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/04更新 · NCT06311214FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- University of Oklahoma - Health Sciences Center, Oklahoma City
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT05614739Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/03更新 · NCT05687110Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/31更新 · NCT05691491A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Stephenson Cancer Center, Oklahoma City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/30更新 · NCT04657068Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/19更新 · NCT05431270Collection and Storage of Tissue and Blood Samples From Patients With Cancer
- Mercy Hospital Oklahoma City, Oklahoma City
被験者募集中観察研究
2 Months · 全性別 · 2026/03/05更新 · NCT02474160Circulating Tumor DNA Response In Urothelial Cancer
- OU Health Stephenson Cancer Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2026/02/02更新 · NCT07183319SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Tulsa
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774Spine Radiosurgery for Symptomatic Metastatic Neoplasms
- OU Health Stephenson Cancer Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2025/10/20更新 · NCT05617716A Study of NX-1607 in Adults With Advanced Malignancies
- University of Oklahoma, Oklahoma City
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/09更新 · NCT05107674ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。